Cybin Inc

#Cybin has evolved into a mature, late-stage biotechnology company —rapidly achieving milestones towards our goal of revolutionizing mental healthcare. Learn more about our pipeline of next-generation treatment options: https://loom.ly/hoNJx50 #MentalHealth #Biotechnology

July is Bebe Moore Campbell National Minority Mental Health Awareness Month, a time to address and enhance minority access to mental health services. At Cybin, we’re focused on developing innovative new treatments to make mental health care more effective and accessible for all. Cybin Inc #MinorityMentalHealthMonth #NMMHAM #MentalHealth #Psychedeli

Happy Independence Day! As we celebrate freedom, let's also remember the importance of mental independence and resilience. At Cybin, we're dedicated to pioneering treatments that empower mental wellbeing for all. #FourthofJuly #MentalHealth #Freedom #IndependenceDay

To date, Cybin has shared positive Phase 2 topline results for CYB003 in participants with Major Depressive Disorder #MDD, evaluating the efficacy and safety of CYB003 with two doses, at up to 4 months. Learn more: https://loom.ly/tZQcow0 ↩️ #researchanddevelopment #psychedelicresearch #clinicalresearch 

🇨🇦 Happy Canada Day! Today, we're reminded of our commitment at Cybin to contribute to the health and well-being of Canadians. Our journey is fueled by innovation, compassion, and the relentless pursuit of advancing mental health care. Here's to a future where every Canadian thrives. #CanadaDay #MentalHealthInnovation #Cybin

This #PrideMonth, Cybinauts are mindful of the disproportionate impact of mental health conditions on #LGBTQ2S+ communities and the urgency of realizing innovative new therapeutic options for all patients in need. Learn more: www.cybin.com #MentalHealth #Biotechnology #loveislove #Psychedelics #illustration #art #pride

#Cybin's #CYB003 received the first known U.S. #FDA Breakthrough Therapy Designation (#BTD) for an adjunctive psychedelic-based therapy for Major Depressive Disorder (#MDD) — validating its potential for significant clinical improvements over existing treatments and accelerating its development pathway towards commercialization. Learn more: https://lnkd.in/g2evfR-g #Biotechnology #MentalHealthInnovation #Psychedelics The recording shared below are the property of the OPEN Foundation and may not be shared without prior authorisation.

Cybin CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright & Co., LLC 5th Annual Neuro Perspectives Virtual Conference tomorrow at 7:00 a.m. ET. Access the webcast here: https://loom.ly/PFkpoLU #MentalHealthInnovation #Biotechnology #Psychedelics

#Cybin has evolved into a mature, late-stage company with critical milestones on the near-term horizon. With #FDA #BTD designation and positive four-month durability data for #CYB003 and the initiation of our Phase 2 study of #CYB004, we are rapidly advancing our mission to change the treatment paradigm for #MDD and #GAD and bring innovative treatment options to patients in need. —Cybin CEO Doug Drysdale Read our full release on fiscal year 2024 and recent business highlights: https://loom.ly/4r6Nng0 #MentalHealthInnovation #Biotechnology #Psychedelics

#MarkYourCalendar: Cybin CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright & Co., LLC 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. The chat will be available on demand beginning Monday, June 27, 2024, at 7:00 a.m. ET. Access the webcast here: https://loom.ly/PFkpoLU #MentalHealthInnovation #Biotechnology #Psychedelics